MCRB News and Press, Seres Therapeutics Inc. From 05/06/24

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates. To access the con...

Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medically vulnerable patient populations Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiom...

2024-03-05 15:33:08 ET Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript March 05, 2024, 08:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege ...

2024-03-05 07:03:41 ET More on Seres Therapeutics Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns Seres Therapeutics reports VOWST prelim. Q4 sales of $10.4M; shares jump Seeking Alpha’s Quant Rating on Seres Therapeutics Hist...

VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts ...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. T...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz’s retirement. Mr. Arkowitz has served as CFO since Ju...

2024-01-30 05:15:11 ET Summary Seres Therapeutics focuses on microbiome therapies, with its leading product VOWST preventing recurrent Clostridioides difficile infection. The company is developing SER-155, which has FDA Fast Track Designation, and has other products in its pipelin...